Innate Pharma S.A. (IPH.PA)
EUR 1.98
(-3.37%)
EUR 1.98
(-3.37%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 51.9 Million EUR | 4.56% |
| 2022 | 49.63 Million EUR | 309.83% |
| 2021 | 12.11 Million EUR | -78.69% |
| 2020 | 56.83 Million EUR | -17.6% |
| 2019 | 68.97 Million EUR | -13.67% |
| 2018 | 79.89 Million EUR | 144.83% |
| 2017 | 32.63 Million EUR | -41.9% |
| 2016 | 56.16 Million EUR | 213.64% |
| 2015 | 17.9 Million EUR | 1874.2% |
| 2014 | 907 Thousand EUR | -92.73% |
| 2013 | 12.46 Million EUR | 20.16% |
| 2012 | 10.37 Million EUR | -11.61% |
| 2011 | 11.74 Million EUR | 171.76% |
| 2010 | 4.32 Million EUR | -44.01% |
| 2009 | 7.71 Million EUR | -40.3% |
| 2008 | 12.92 Million EUR | -9.56% |
| 2007 | 14.29 Million EUR | 130.67% |
| 2006 | 6.19 Million EUR | 376.54% |
| 2005 | 1.3 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 6.17 Million EUR | -42.43% |
| 2024 Q2 | 6.17 Million EUR | 0.0% |
| 2023 Q4 | 10.72 Million EUR | 0.0% |
| 2023 Q3 | 10.72 Million EUR | -69.67% |
| 2023 Q1 | 20.09 Million EUR | 141.89% |
| 2023 FY | 51.9 Million EUR | 4.56% |
| 2023 Q2 | 35.34 Million EUR | 75.85% |
| 2022 FY | 49.63 Million EUR | 309.83% |
| 2022 Q1 | 22.79 Million EUR | 716.13% |
| 2022 Q2 | 41.27 Million EUR | 81.06% |
| 2022 Q3 | 6.04 Million EUR | -85.36% |
| 2022 Q4 | 8.3 Million EUR | 37.51% |
| 2021 Q1 | 6.65 Million EUR | -75.34% |
| 2021 FY | 12.11 Million EUR | -78.69% |
| 2021 Q3 | 5.69 Million EUR | -38.88% |
| 2021 Q2 | 9.31 Million EUR | 40.01% |
| 2021 Q4 | 2.79 Million EUR | -50.96% |
| 2020 FY | 56.83 Million EUR | -17.6% |
| 2020 Q1 | 18.37 Million EUR | 5.67% |
| 2020 Q4 | 26.99 Million EUR | 60.16% |
| 2020 Q3 | 16.85 Million EUR | -43.52% |
| 2020 Q2 | 29.84 Million EUR | 62.42% |
| 2019 Q2 | 51.58 Million EUR | 74.42% |
| 2019 Q3 | 13.32 Million EUR | -74.16% |
| 2019 Q4 | 17.38 Million EUR | 30.43% |
| 2019 FY | 68.97 Million EUR | -13.67% |
| 2019 Q1 | 29.57 Million EUR | -16.63% |
| 2018 Q1 | 11.49 Million EUR | 1.04% |
| 2018 FY | 79.89 Million EUR | 144.83% |
| 2018 Q4 | 35.47 Million EUR | 0.0% |
| 2018 Q3 | 35.47 Million EUR | 208.56% |
| 2018 Q2 | 11.49 Million EUR | 0.0% |
| 2017 Q1 | 10.63 Million EUR | -52.76% |
| 2017 FY | 32.63 Million EUR | -41.9% |
| 2017 Q4 | 11.37 Million EUR | 0.0% |
| 2017 Q3 | 11.37 Million EUR | 6.98% |
| 2017 Q2 | 10.63 Million EUR | 0.0% |
| 2016 Q2 | 10.34 Million EUR | 0.0% |
| 2016 FY | 56.16 Million EUR | 213.64% |
| 2016 Q4 | 22.51 Million EUR | 0.0% |
| 2016 Q3 | 22.51 Million EUR | 117.72% |
| 2016 Q1 | 10.34 Million EUR | 0.9% |
| 2015 Q1 | 2.32 Million EUR | 33.1% |
| 2015 FY | 17.9 Million EUR | 1874.2% |
| 2015 Q2 | 2.32 Million EUR | 0.0% |
| 2015 Q4 | 10.25 Million EUR | 0.0% |
| 2015 Q3 | 10.25 Million EUR | 341.83% |
| 2014 Q3 | 1.74 Million EUR | -15.74% |
| 2014 Q1 | 2.06 Million EUR | -57.23% |
| 2014 Q2 | 2.06 Million EUR | 0.0% |
| 2014 Q4 | 1.74 Million EUR | 0.0% |
| 2014 FY | 907 Thousand EUR | -92.73% |
| 2013 Q3 | 4.83 Million EUR | 38.62% |
| 2013 Q1 | 3.48 Million EUR | 6.32% |
| 2013 FY | 12.46 Million EUR | 20.16% |
| 2013 Q4 | 4.83 Million EUR | 0.0% |
| 2013 Q2 | 3.48 Million EUR | 0.0% |
| 2012 Q4 | 3.28 Million EUR | 0.0% |
| 2012 FY | 10.37 Million EUR | -11.61% |
| 2012 Q3 | 3.28 Million EUR | 0.0% |
| 2011 FY | 11.74 Million EUR | 171.76% |
| 2010 FY | 4.32 Million EUR | -44.01% |
| 2009 FY | 7.71 Million EUR | -40.3% |
| 2008 FY | 12.92 Million EUR | -9.56% |
| 2007 FY | 14.29 Million EUR | 130.67% |
| 2006 FY | 6.19 Million EUR | 376.54% |
| 2005 FY | 1.3 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -1018.556% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -1023.155% |
| Adocia SA | 2.15 Million EUR | -2314.0% |
| Aelis Farma SA | 9.05 Million EUR | -473.238% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -1547.128% |
| genOway Société anonyme | 20.04 Million EUR | -158.905% |
| IntegraGen SA | 12.53 Million EUR | -313.968% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -17198.373% |
| Neovacs S.A. | 533.41 Thousand EUR | -9630.002% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -2986.562% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -262079.228% |
| Sensorion SA | 4.74 Million EUR | -994.25% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -17414.536% |
| TME Pharma N.V. | 17 Thousand EUR | -305200.0% |
| Valbiotis SA | 4.73 Million EUR | -996.577% |
| TheraVet SA | 1.07 Million EUR | -4714.318% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -2783.389% |
| argenx SE | 1.13 Billion EUR | 95.424% |
| BioSenic S.A. | 543 Thousand EUR | -9458.195% |
| Celyad Oncology SA | 102 Thousand EUR | -50783.333% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 78.35% |
| Genfit S.A. | 28.56 Million EUR | -81.694% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -2386.871% |
| Inventiva S.A. | 17.47 Million EUR | -196.967% |
| MaaT Pharma SA | 2.22 Million EUR | -2229.488% |
| MedinCell S.A. | 9.16 Million EUR | -466.605% |
| Nanobiotix S.A. | 30.05 Million EUR | -72.67% |
| Onward Medical N.V. | 532 Thousand EUR | -9655.827% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -265.716% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -2230.534% |
| Oxurion NV | 263 Thousand EUR | -19634.221% |
| Pharming Group N.V. | 245.31 Million EUR | 78.843% |
| Poxel S.A. | 1.98 Million EUR | -2519.939% |
| GenSight Biologics S.A. | 1.26 Million EUR | -3996.369% |
| Transgene SA | 1.18 Million EUR | -4283.53% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.012% |
| Valneva SE | 153.71 Million EUR | 66.235% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 1533.729% |